March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.